Medtronic Wins Dual Cardiac Clearances While MiniMed Swap and Robotics Push Reshape the Group

Medtronic gained FDA clearance and CE marks for cardiac ablation tools as its MiniMed exchange offer runs to Oct. 9 and a $0.72 dividend is declared.

Medtronic has secured a pair of regulatory green lights for its heart-rhythm franchise, even as a broader corporate overhaul and a fresh dividend declaration dominate the agenda for shareholders.

The medical-technology group said it received FDA clearance and the CE mark for its Affera Prism-2 mapping software, and separately obtained CE certification for the PulseSelect ProxBox adapter, which carries integrated proximity-indicator software. Together the approvals deepen Medtronic's hand in cardiac ablation: Prism-2 adds tissue-mapping tools to the clinical toolkit, while the ProxBox adapter feeds physicians real-time feedback on tissue proximity, a feature meant to sharpen precision during cardiology procedures.

A Quiet Tape Despite the Headlines

Investors took the news in stride. The stock changed hands at EUR 76.50, a modest 0.4% decline, putting the company's market value at roughly EUR 100.01 billion. The muted reaction echoes a pattern of recent sessions in which product milestones have failed to jolt the share price.

Insider activity offered another data point. Harry "Skip" Kiil, Executive Vice President and Cardiovascular President, sold 1,483 common shares on September 16 at USD 93.65 apiece. The mandatory disclosure listed a remaining holding of 42,186 shares.

MiniMed Exchange Offer in Motion

The cardiac clearances land amid a far-reaching strategic reset. Medtronic is pressing ahead with the separation of its diabetes unit, MiniMed, through an exchange offer launched about two weeks ago — a move that has since coincided with a 5.9% slide in the stock. Shareholders can tender up to 225,361,295 MiniMed shares in return for Medtronic common stock, a structure designed to complete the spin-off of at least 80.1% of the unit. Should the offer be oversubscribed, Medtronic has reserved the right to add a further 27,452,053 shares. The offer is scheduled to run until October 9, 2026.

The mechanics give participants a 7% discount when swapping Medtronic stock into MiniMed shares, capped at 4.5939 MiniMed shares per Medtronic share. If that ceiling does not bite, tendering holders would receive roughly USD 107.53 of MiniMed stock for every USD 100 of Medtronic shares submitted. MiniMed had already gone public in March 2026, with Medtronic retaining an ownership stake of about 90% at the time. Management frames the transaction as a way to sharpen capital allocation and give the balance sheet more room to maneuver.

Dividend on the Calendar

For income-focused holders, the board declared a cash dividend of USD 0.72 per common share for the second quarter of fiscal 2027. It is payable on October 16, 2026 to shareholders of record as of September 25, 2026. The payout arrives as the stock has steadied, quoted at EUR 76.86 and carrying the same EUR 100.01 billion market capitalization.

Robotics Ambitions Take Shape

Running parallel to the separation is an aggressive build-out in robot-assisted surgery. Roughly a month ago Medtronic struck a strategic partnership worth USD 700 million with Cornerstone Robotics, a deal that includes distribution rights for the Sentire surgical system in selected markets outside the United States. Sentire picked up CE certification in May 2026 for minimally invasive procedures across general surgery, gynecology, thoracic surgery and urology.

On the Hugo front, the FDA cleared the LigaSure RAS Maryland tissue instrument for U.S. use on September 16, following an earlier approval for a different Hugo instrument more than a month ago — a stock that has since climbed 285.2%. Analysts at Needham, writing on September 18, characterized the Cornerstone Robotics tie-up as a complement to Hugo that could extend Medtronic's reach in robotic surgery.

Guidance Backed by a Solid Start

The restructuring rests on a firm operational footing. Adjusted diluted earnings per share came in at USD 1.45, ahead of prior expectations. Buoyed by that beat, management raised its full-year targets roughly three weeks ago, lifting the organic revenue growth range for fiscal 2027 by 50 basis points to between 7.25% and 7.75%. Adjusted EPS is now projected at USD 5.94 to USD 6.00. A multibillion-dollar realignment, targeted acquisitions and a scheduled dividend together form the scaffolding for the months ahead, with the cardiac approvals adding fresh product momentum to the mix.